ERRATA

The March 10, 2009, article by Escudier et al, entitled “Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma” (J Clin Oncol 27:1280-1289, 2009), contained errors.

In Figure 1, two of the treatment boxes were inadvertently transposed, and the label for Period 2 was misplaced. The corrected figure is reprinted below in its entirety. The online version has been corrected in departure from the print.

Fig 1. Study design schematic. Abbreviations: AEs, adverse events; ECOG, Eastern Cooperative Oncology Group; IFN, interferon alfa-2a; MSKCC, Memorial Sloan-Kettering Cancer Center; MIU, million units.

DOI: 10.1200/JCO.2009.23.1290

The March 20, 2009, article by Bookman et al, entitled “Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup” (J Clin Oncol 27:1419-1425, 2009), contained an error.

In Figure 3B, the y-axis was labeled as Progression-Free Survival, whereas it should have been Overall Survival.

DOI: 10.1200/JCO.2009.23.1308